·糖尿病临床研究·

　　【摘要】 目的 观察利拉鲁肽治疗新诊断T2DM患者的临床疗效。 方法 48例新诊断T2DM患者被随机分为利拉鲁肽组和二甲双胍组，每组各24例。 结果 治疗12周后，两组FPG、2 hPG、HbA1c、体重、HOMA-IR及血脂等差异均有统计学意义(P<0.01)，利拉鲁肽组优于二甲双胍组(P<0.05)，且利拉鲁肽组C-P水平治疗后明显提高(P<0.01)。 结论 利拉鲁肽用于治疗新诊断T2DM患者，安全有效。

　　【关键词】 利拉鲁肽; 二甲双胍; 糖尿病，2型

Effects of liraglutide for the treatment of newly diagnosed type 2 diabetes LU Jing-er, REN Yue-zhong, GONG Wei-kun, et al. Department of Endocrinology, Ningbo Yinzhou Hospital, Ningbo 315040, China

　　【Abstract】 Objective To observe the clinical efficacy of liraglutide in treatment of patients with newly diagnosed T2DM. Methods A total of 48 T2DM patients were randomly divided into the liraglutide group and the metformin group. Results After 12-week treatment, the levels of FPG, 2 hPG,HbA1c, BMI, body weight, insulin resistance index and blood lipid were significantly improved in both groups (all P<0.01), and liraglutide group had superior improvements (P<0.05). The C-P levels were obviously increased in the liraglutide group after 12 weeks of treatment(P<0.01). There was statistically significant differences between the two groups(P<0.05). Conclusion Liraglutide is an efficacious and safe hypoglycemic medication for treatment of T2DM.

　　【Key words】 Liraglutide; Metformin; Diabetes mellitus, type 2